Brief: Oncolys BioPharma invests in US Biotech Venture Specialized in Development of Novel Oncolytic Adenovirus
16/02/2018 09:33
Feb 16 (Reuters) - Oncolys BioPharma Inc 4588.T
* Says it will enter into an investment and share transfer
agreement with Unleash Immuno Oncolytics, Inc., a biotech
venture specialized in development of novel oncolytic adenovirus
* Says it agrees to purchase $3 million convertible bonds
issued
by Unleash with the expected voting rights ratio of
approximately 27 percent, when fully converted
* Says it also agrees to purchase 294,118 ordinary shares of
Precision Virologics held by Unleash for $330,000, which will
increase Oncolys' voting rights ratio of Precision to 23
percent, approximately
Source text in Japanese:https://goo.gl/y23PMq
Further company coverage: 4588.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +8601082555111;
Reuters Messaging: Pingping.Li1@thomsonreuters.com@reuters.net))